Intracavernosal Injections for Premature Ejaculation

Intracavernosal injection (ICI) therapy is primarily a treatment for erectile dysfunction. For men whose premature ejaculation overlaps with ED, it can help maintain a firm erection through and after climax, which supports continued intimacy and a greater sense of control. It is a specialized, provider-directed option rather than a standard PE treatment.

No. First-line medication approaches for PE are typically SSRIs (such as sertraline) and topical numbing agents. ICI is considered in the specific situation where PE and ED occur together, and a provider determines whether it fits your case.

The injection delivers vasodilating medication directly into the penis, producing an erection usually within about 5 to 15 minutes that can be sustained through and after ejaculation. Because it acts on blood flow rather than on ejaculation timing itself, it addresses the erection side of overlapping PE and ED.

The best candidates are generally men who experience both premature ejaculation and difficulty maintaining an erection, especially loss of firmness after climax. Revibe’s providers evaluate your PE and ED together to decide whether this approach is appropriate.

Yes. As with all injection therapy, correct site, technique, and dose matter for safety and results, so your provider trains you before you self-administer at home and titrates the dose carefully.

ICI is designed to maintain the erection, not to directly delay ejaculation; men who need help with ejaculation timing itself may also be offered a separate PE treatment. Your provider will build a plan around your specific combination of concerns.

Because using ICI in the context of PE is a specialized application, it should be prescribed only after a provider has evaluated how your PE and ED interact. Revibe’s providers tailor and monitor the treatment accordingly.

Possible effects include penile pain or aching, minor bruising, and—most importantly—a prolonged erection (priapism), which is a medical emergency if it lasts more than four hours. Long-term use can cause scar tissue at injection sites. Provider monitoring helps manage these risks.